Relay Therapeutics (RLAY)
NASDAQ:RLAY
US Market

Relay Therapeutics (RLAY) Stock Price & Analysis

199 Followers

RLAY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$9.67 - $33.06
Previous Close$11
Volume1.15M
Average Volume (3M)1.62M
Market Cap
$1.34B
Enterprise Value$1.23B
Total Cash (Recent Filing)$161.28M
Total Debt (Recent Filing)$56.75M
Price to Earnings (P/E)-3.9
Beta1.74
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.80
Shares Outstanding121,613,181
10 Day Avg. Volume1,404,552
30 Day Avg. Volume1,618,335
Standard Deviation0.19
R-Squared0.13
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.60
Price to Sales (P/S)5919.23
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.04K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.60
Forecast
Price Target Upside155.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11


Financials

Annual

RLAY FAQ

What was Relay Therapeutics’s price range in the past 12 months?
Relay Therapeutics lowest stock price was $9.67 and its highest was $33.06 in the past 12 months.
    What is Relay Therapeutics’s market cap?
    Currently, no data Available
    When is Relay Therapeutics’s upcoming earnings report date?
    Relay Therapeutics’s upcoming earnings report date is Aug 10, 2023 which is in 74 days.
      How were Relay Therapeutics’s earnings last quarter?
      Relay Therapeutics released its earnings results on May 04, 2023. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.691 by -$0.089.
        Is Relay Therapeutics overvalued?
        According to Wall Street analysts Relay Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Relay Therapeutics pay dividends?
          Relay Therapeutics does not currently pay dividends.
          What is Relay Therapeutics’s EPS estimate?
          Relay Therapeutics’s EPS estimate is -$0.8.
            How many shares outstanding does Relay Therapeutics have?
            Relay Therapeutics has 121,613,180 shares outstanding.
              What happened to Relay Therapeutics’s price movement after its last earnings report?
              Relay Therapeutics reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.691. Following the earnings report the stock price went up 0.446%.
                Which hedge fund is a major shareholder of Relay Therapeutics?
                Among the largest hedge funds holding Relay Therapeutics’s share is Perceptive Advisors LLC. It holds Relay Therapeutics’s shares valued at 32M.

                  ---

                  Relay Therapeutics Stock Smart Score

                  The Relay Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Relay Therapeutics

                  Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.

                  ---

                  Top 5 ETFs holding RLAY

                  Name
                  Market Value
                  Smart Score
                  iShares Biotechnology ETF
                  $6.93M
                  8
                  Vanguard Health Care ETF
                  $3.13M
                  8
                  iShares NASDAQ US Biotechnology UCITS ETF
                  $674.16K
                  8
                  Fidelity Nasdaq Composite Index ETF
                  $553.10K
                  8
                  Fidelity MSCI Health Care Index ETF
                  $475.02K
                  8
                  Up to five ETFs with an Outperform Smart Score that hold RLAY. The ETFs are listed according to market value of RLAY within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Insmed
                  ACADIA Pharmaceuticals
                  BioCryst
                  SAGE Therapeutics
                  Arcus Biosciences

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis